Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/91058
Título: | Intravitreal injection of adenosine A2A receptor antagonist reduces neuroinflammation, vascular leakage and cell death in the retina of diabetic mice | Autor: | Aires, Inês Dinis Madeira, Maria Helena Boia, Raquel Rodrigues-Neves, Ana Catarina Martins, Joana Margarida Ambrósio, António Francisco Santiago, Ana Raquel |
Palavras-chave: | Nitric-Oxide Synthase; Ganglion-Cells; Microglial activation; Retinopathy; Rat; Inflammation; Model; Neurodegeneration; Degeneration; Apoptosis | Data: | 20-Nov-2019 | Editora: | NATURE PUBLISHING GROUP | Projeto: | Bayer AG European Union (EU) Portuguese Foundation for Science and Technology Centro 2020 Regional Operational Programme (BRAINHEALTH 2020) |
Título da revista, periódico, livro ou evento: | Scientific Reports | Volume: | 9 | Número: | 17207 | Local de edição ou do evento: | MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND | Resumo: | Diabetic retinopathy is a major complication of diabetes mellitus and a leading cause of blindness. The pathogenesis of diabetic retinopathy is accompanied by chronic low-grade inflammation. Evidence shows that the blockade of adenosine A2A receptors (A2AR) affords protection to the retina through the control of microglia-mediated neuroinflammation. Herein, we investigated the therapeutic potential of an antagonist of A2AR in a model of diabetic retinopathy. Type 1 diabetes was induced in 4-5 months old C57BL/6 J mice with a single intraperitoneal injection streptozotocin. Animals were treated one month after the onset of diabetes. The A2AR antagonist was delivered by intravitreal injection once a week for 4 weeks. Microglia reactivity and inflammatory mediators were increased in the retinas of diabetic animals. The treatment with the A2AR antagonist was able to control microglial reactivity and halt neuroinflammation. Furthermore, the A2AR antagonist rescued retinal vascular leakage, attenuated alterations in retinal thickness, decreased retinal cell death and the loss of retinal ganglion cells induced by diabetes. These results demonstrate that intravitreal injection of the A2AR antagonist controls inflammation, affords protection against cell loss and reduces vascular leakage associated with diabetes, which could be envisaged as a therapeutic approach for the early complications of diabetes in the retina. | URI: | https://hdl.handle.net/10316/91058 | ISSN: | 2045-2322 | DOI: | 10.1038/s41598-019-53627-y | Direitos: | openAccess |
Aparece nas coleções: | I&D IBILI - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
41598_2019_Article_53627.pdf | 5.08 MB | Adobe PDF | Ver/Abrir |
Citações SCOPUSTM
18
Visto em 14/out/2024
Citações WEB OF SCIENCETM
10
19
Visto em 2/out/2024
Visualizações de página
263
Visto em 15/out/2024
Downloads
220
Visto em 15/out/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons